MRNA
Moderna, Inc.
NasdaqGS · USD · Stock
$221.72
+18.26 (+8.97%)
past month
Closed- Market cap
- $88.52B
- Volume
- 9M
- 52 weeks
- $22.28 – $254
About
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Moderna, Inc. (MRNA) is a healthcare company listed on Nasdaq, traded in USD. Over the past year it moved between $22.28 and $254.48.
- Healthcare
- Biotechnology
- Cambridge, United States
- 4.7K employees
- Led by Stéphane Bancel M.B.A.
Coming up
Earnings
Next report
Expected EPS -$1.35 · revenue $891.31M
Financials
Revenue, last 12 months
$2.23B+2.10%
Earnings
Beat the estimate
4 of 4 quarters
Q3 2025
+76.60%
Q4 2025
+18.88%
Q1 2026
+12.37%
Q2 2026
+4.33%
Earnings per share, last 12 months -$7.98
Analysts
19 analysts say
Hold
12-month target$138.37-37.59%
Ownership
- Institutions
- 80.49%
- Insiders
- 7.36%
Latest insider trade Oct 5, 2026, MOCK JAMES M
Prices from Yahoo Finance, may be delayed
